Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Enlivex Therapeutics Ltd
ENLV
Healthcare
Biotechnology
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages...
out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:ENLV)
New Post
View:
Posts & Comments
Threaded Posts
(267)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Sep 26, 2024 2:31pm
Enlivex Receives Authorization from the Danish Medicines Age
Just In: $ENLV Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee
...more
(59)
•••
Nibinator
X
View Profile
View Bullboard History
Post by
Nibinator
on Jun 26, 2024 8:25pm
BUY BUY BUY BUY BUY
Whytestock is right on the news this thing alocentra gonna be first and only fda approuved
Discover Options Trading Strategies to Minimize your Tax Burden
posted Nov 30, 2024 9:00am by
Bank of Montreal
-
|
Options trading doesn’t come without tax implications, but there are ways investors can still optimize their after-tax returns with just a little bit of understanding. Approaches for investors to keep in mind are holding periods, wash-sales rule, tax advantaged accounts, and qualified cover calls. BMO’s enhanced InvestorLine platform. Industry-leading tools and capabilities specifically designed to empower options traders. ...read more
(267)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jun 24, 2024 4:30pm
Enlivex Announces the Dosing of the First Patient in a Rando
BREAKING NEWS: $ENLV Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb OsteoarthritisFirst
...more
(267)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Apr 29, 2024 2:45pm
Enlivex CEO Issues Letter to Shareholders - Perspectives on
News; $ENLV Enlivex CEO Issues Letter to Shareholders - Perspectives on Recent EventsNes-Ziona, Israel, April 29, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “
...more
(0)
•••
HariboSpeedPeak
X
View Profile
View Bullboard History
Post by
HariboSpeedPeak
on Jul 21, 2022 4:55pm
H.C. Wainwright Article on Enlivex
Worth the read for investors and potential investors, https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-a-buy-rating-on-enlivex-therapeutics-enlv
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >